Summary
No overall score for this company yet.
What speaks for it
- Revenue grew by 408% a year over the last 3 years.
- It holds more cash than debt: $697.3M against $15.2M.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 12 USD is left as net profit.
What to watch
- It earns only 4.9 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 20.9 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
- Analyst estimate
Revenue grew by 0.1% a year over 5 years. Over the last 3 years it grew by 408% a year. Earnings per share grew by 5.8% a year over the last 3 years.
Growth in detailDoes it make money?
Where 100 USD of revenue goes
- Cost of sales 41 USD
- Sales and administration 48 USD
- Taxes and other -0.7 USD
- Net profit 12 USD
Net profit, industry median (Medical - Pharmaceuticals) 5.0 USD
Out of every 100 USD of revenue, 12 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.